AC
NTLA icon

Alexandria Capital’s Intellia Therapeutics NTLA Stock Holding History

Alexandria Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$215K Sell
1,600
-120
-7% -$18.2K 0.02% 240
2021
Q2 		$278K Buy
+1,720
New +$134K 0.03% 228

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Alexandria Capital's NTLA Position: Q3 2021 in Review

Alexandria Capital reduced its Intellia Therapeutics (NTLA) stake by 7% in Q3 2021, selling an estimated $18.2K and leaving 1,600 shares worth $215K. The position accounts for 0.02% of the portfolio, ranked #240.

Alexandria Capital first reported a position in NTLA in Q2 2021 and has held it in 2 quarters since. The position peaked at $278K in Q2 2021. 365 funds tracked by Wall St. Rank hold NTLA as of Q3 2021.

  • Alexandria Capital held 1,600 shares of Intellia Therapeutics worth $215K as of Q3 2021.
  • Alexandria Capital sold 120 Intellia Therapeutics shares in Q3 2021, an estimated $18.2K.
  • Intellia Therapeutics made up 0.02% of Alexandria Capital's portfolio in Q3 2021, its #240 holding.
  • Alexandria Capital first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • Alexandria Capital's Intellia Therapeutics position peaked at $278K in Q2 2021.
  • 365 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2021.

Based on Alexandria Capital's 13F filing for Q3 2021, filed 2 Dec 2021.